Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001012 | 1.00 | PDGFRB (0.53) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL502591 | 0.88 | PDGFRB (0.53) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL28113289 | 0.85 | MAPT (0.50) | ALDH1A1TDP1TSHRMAPTCYP3A4 | |
| SCHEMBL2133926 | 0.85 | CYP1A2 (0.68) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL29777188 | 0.85 | CYP1A2 (0.68) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1626187 | 0.84 | GAA (0.58) | ALDH1A1MAPTCYP1A2CYP3A4KMT2A | |
| SCHEMBL6597479 | 0.84 | CYP1A2 (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL31037350 | 0.84 | CYP1A2 (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL16619742 | 0.84 | CYP1A2 (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1625685 | 0.84 | MAPT (0.49) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4400493-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-117980293-A | Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof | 上海海和药物研究开发股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023036289-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-03-16 | — | — | WO | disclosed |
| EP-1590314-B1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2015-08-05 | — | — | EP | disclosed |
| CN-101967146-B | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC | 2015-04-08 | — | — | CN | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2011-08-11 | — | — | US | disclosed |
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| CN-1476448-A | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ������ҩ������˾ | 2004-02-18 | — | — | CN | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PDGFRB 2355/4885FGFR1 512/4885PDGFRA 1177/4885 |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, MMP8, CXCR1 | PDGFRB 811/4885FGFR1 397/4885PDGFRA 492/4885 |
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | ENPP1, ENPP2, ENPP3 | PDGFRB 2367/4885FGFR1 1221/4885PDGFRA 2127/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | PDGFRB 608/4885FGFR1 2642/4885PDGFRA 542/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | PDGFRB 371/4885FGFR1 1644/4885PDGFRA 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.